SEC Contract Filing

Filing Date: 2021-04-01

Document Content:
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>16
<FILENAME>ex10-13.htm
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND
AMENDMENT TO THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
AND ASSUMPTION AGREEMENT (U.S.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECOND AMENDMENT TO THE ASSIGNMENT AND ASSUMPTION AGREEMENT (U.S.) (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as
of October 2, 2020, by and among Jay Pharma Inc., a Canada corporation (&ldquo;<B>Company</B>&rdquo;), Tikkun Pharma, Inc., a Delaware
corporation (&ldquo;<B>TP</B>&rdquo;), and TO Pharmaceuticals USA LLC, a Delaware limited liability company (&ldquo;<B>TOP</B>&rdquo;),
and amends that certain Assignment and Assumption Agreement, dated as of January 10, 2020 (the &ldquo;<B>Assignment and Assumption Agreement</B>&rdquo;),
by and among Company, TP and TOP, as amended by that certain First Amendment to the Assignment and Assumption Agreement (U.S.), dated
as of August 12, 2020 (the &ldquo;<B>First Amendment</B>&rdquo; and, together with the Assignment and Assumption Agreement, the &ldquo;<B>Agreement</B>&rdquo;).
Capitalized terms used but not defined herein have their respective meanings set forth in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Amendments</U>.
In accordance with the terms and conditions of the Agreement, the Agreement shall be amended as follows, effective as of the date
hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
 Recitals to the Agreement are hereby deleted and replaced in their entirety by the following:</FONT></TD></TR>
 </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>WHEREAS</B>,
TP has previously entered into that certain Amended and Restated Sublicense Agreement (U.S.) dated January 12, 2018 (as amended by that
certain First Amendment dated January 10, 2020, the &ldquo;<B>Sublicense</B>&rdquo;), pursuant to which TOP sublicensed to TP certain
rights in-licensed from Tikun Olam, Ltd., an Israeli corporation with registration number 514263771;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
in exchange for certain equity consideration as further described herein, TP wishes to transfer and assign to JP, and JP wishes to receive
and assume from TP, (i) any and all of TP&rsquo;s rights and responsibilities under the Sublicense; and (ii) the skincare business developed
under Sarah Dakar and/or Michael Indursky, including without limitation all related tradenames, knowledge, formulations, documentation,
confidential information, customer and supplier lists, and packaging, and any trademarks, patents, copyrights, trade secrets, or other
intellectual property relating to any of the foregoing (collectively, the &ldquo;<B>Skincare Business</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10p